AR034371A1 - PHARMACEUTICAL COMPOSITIONS - Google Patents

PHARMACEUTICAL COMPOSITIONS

Info

Publication number
AR034371A1
AR034371A1 ARP020102106A ARP020102106A AR034371A1 AR 034371 A1 AR034371 A1 AR 034371A1 AR P020102106 A ARP020102106 A AR P020102106A AR P020102106 A ARP020102106 A AR P020102106A AR 034371 A1 AR034371 A1 AR 034371A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
ophthalmic
eye
day
useful
Prior art date
Application number
ARP020102106A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR034371A1 publication Critical patent/AR034371A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Las composiciones oftálmicas que comprende un fármaco oftálmico y un compuesto de polisacárido lineal son útiles para la adminsitración tópica una vez al día al ojo.Ophthalmic compositions comprising an ophthalmic drug and a linear polysaccharide compound are useful for topical administration once a day to the eye.

ARP020102106A 2001-06-08 2002-06-06 PHARMACEUTICAL COMPOSITIONS AR034371A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01113958 2001-06-08
EP01113959 2001-06-08
EP01115096 2001-06-21
EP01115097 2001-06-21

Publications (1)

Publication Number Publication Date
AR034371A1 true AR034371A1 (en) 2004-02-18

Family

ID=27440131

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020102106A AR034371A1 (en) 2001-06-08 2002-06-06 PHARMACEUTICAL COMPOSITIONS

Country Status (9)

Country Link
EP (1) EP1404370A2 (en)
JP (1) JP2005508866A (en)
CN (1) CN1514735A (en)
AR (1) AR034371A1 (en)
AU (1) AU2002314149A1 (en)
BR (1) BR0210139A (en)
CA (1) CA2449213A1 (en)
PE (1) PE20030206A1 (en)
WO (1) WO2002100437A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345015A1 (en) * 2001-06-08 2002-12-23 Novartis Pharma Gmbh Ophthalmic once-a-day composition
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
JP2004143155A (en) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd Ophthalmic solution
US20040137079A1 (en) * 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
EP1661573B1 (en) * 2003-08-21 2013-09-25 Sucampo AG Ophtalmic composition comprising unoprostone ispopropyl ester and a viscosity agent
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
EP1706095B1 (en) * 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
DE102005035986B4 (en) * 2005-07-28 2009-10-15 Bausch & Lomb Incorporated Sterile drippable multiphase emulsifier-free ophthalmic preparation
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN100408046C (en) * 2005-12-22 2008-08-06 涂家生 Macrolide antibiotics sodium hyaluronate eye transfer system
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
CA2813734A1 (en) * 2010-10-04 2012-04-12 Activbiotics Pharma, Llc Use of rifalazil and analogues thereof to treat ocular disorders
KR101412776B1 (en) 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 Eye drop composition for treating keratoconjunctivitis and preparation method of the same
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
EP3500255B1 (en) 2016-08-19 2022-11-30 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (en) * 1985-04-05 1991-07-17 Fidia Farmaceutici Topical compsn. contg. hyaluronic acid deriv. as vehicle
RU2089191C1 (en) * 1994-01-28 1997-09-10 Научно-производственная фирма "Нарт" Method of prolongation of physiological effect of thymolol with respect to intraocular pressure decreasing
CA2193149C (en) * 1995-12-22 2002-04-23 David H. Donabedian Cationic therapuetic agents and delivery systems
JPH1160505A (en) * 1997-05-20 1999-03-02 Senju Pharmaceut Co Ltd Antiseptic composition
DE19923829A1 (en) * 1999-05-17 2000-11-23 Ulrich Kluegel Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent
US6777429B1 (en) * 1999-07-23 2004-08-17 Novartis Ag Ophthalmic composition

Also Published As

Publication number Publication date
BR0210139A (en) 2004-06-08
WO2002100437A2 (en) 2002-12-19
CA2449213A1 (en) 2002-12-19
EP1404370A2 (en) 2004-04-07
WO2002100437A3 (en) 2003-04-24
JP2005508866A (en) 2005-04-07
CN1514735A (en) 2004-07-21
PE20030206A1 (en) 2003-04-09
AU2002314149A1 (en) 2002-12-23

Similar Documents

Publication Publication Date Title
AR034371A1 (en) PHARMACEUTICAL COMPOSITIONS
RS51569B (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
DE60205749D1 (en) ORAL DRUG COMPOSITIONS TO BE APPLIED WITH A TAXED ACTIVE SUBSTANCE
NO2011025I1 (en) Telavancin, or a pharmaceutically acceptable salt thereof, including including telavancin hydrochloride
AR005703A1 (en) SUBSTITUTED OXAZOLIDINONES, PROCEDURE FOR THE PREPARATION, USE OF THE SAME TO PREPARE MEDICINES AND MEDICINES THAT CONTAIN THEM
CO5050297A1 (en) USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C
CR7921A (en) PALONOSETRON LIQUID PHARMACEUTICAL FORMULATIONS
AR034213A1 (en) COMPOSITIONS OF DRUGS ON THE BASE OF ANTI-POLINERGIC AGENTS AND INHIBITORS OF PDE-IV
EE200300311A (en) Phthalazinone-piperidine derivatives, their use and medicine
TR200201174T2 (en) Pharmaceutical compositions containing fluoroquinolone antibiotic medicine and xanthan gum.
DE60327693D1 (en) TOPICAL COMPOSITION CONTAINING A CYCLOFRUCTAN, A CARRIER AND A MEDICAMENT
DE69923336D1 (en) ORANGE BUPRENORPHINIC MEDICINAL PRODUCTS TO BE APPLIED
CR6834A (en) COMPLEXES AND COMPOSITIONS OF MACROMOLECULAR DRUGS CONTAINING THE SAME
HRP20070291T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
BRPI0611526A2 (en) topical composition containing gelatin
AR034372A1 (en) PHARMACEUTICAL COMPOSITIONS
ATE345776T1 (en) OSMOTIC ADMINISTRATION SYSTEM
EE200300129A (en) Use of distamycin alpha-haloacryloyl derivative
DE60217315D1 (en) PHARMACEUTICAL COMPOSITIONS OF RAPAMYCINES
ATE297760T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING TERBINAFIN
DE60312642D1 (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE
ITMI20020872A1 (en) HYPERPHORINE DERIVATIVES THEIR USE AND FORMULATIONS CONTAINING THEM
SV2003001422A (en) "1,3-DIARILPROP-2-EN-1-ONAS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE"
ITMI20020921A1 (en) DRUG ADMINISTRATION DEVICE
BRPI0410638A (en) azithromycin derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure